These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 39063989)

  • 1. Dupilumab Improves Facial Pain and Reduces Rescue Treatments in Patients with CRSwNP and Recalcitrant Frontal Sinusitis.
    De Corso E; Settimi S; Penazzi D; D'Agostino G; Corbò M; Rigante M; Montuori C; Rizzuti A; Pacilli MC; Di Cesare T; Lo Verde S; Rizzi A; Chini R; Galli J
    J Pers Med; 2024 Jul; 14(7):. PubMed ID: 39063989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
    Bachert C; Han JK; Desrosiers M; Hellings PW; Amin N; Lee SE; Mullol J; Greos LS; Bosso JV; Laidlaw TM; Cervin AU; Maspero JF; Hopkins C; Olze H; Canonica GW; Paggiaro P; Cho SH; Fokkens WJ; Fujieda S; Zhang M; Lu X; Fan C; Draikiwicz S; Kamat SA; Khan A; Pirozzi G; Patel N; Graham NMH; Ruddy M; Staudinger H; Weinreich D; Stahl N; Yancopoulos GD; Mannent LP
    Lancet; 2019 Nov; 394(10209):1638-1650. PubMed ID: 31543428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologics for chronic rhinosinusitis.
    Chong LY; Piromchai P; Sharp S; Snidvongs K; Philpott C; Hopkins C; Burton MJ
    Cochrane Database Syst Rev; 2020 Feb; 2(2):CD013513. PubMed ID: 32102112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: Results from two randomized placebo-controlled phase 3 trials.
    Mullol J; Laidlaw TM; Bachert C; Mannent LP; Canonica GW; Han JK; Maspero JF; Picado C; Daizadeh N; Ortiz B; Li Y; Ruddy M; Laws E; Amin N
    Allergy; 2022 Apr; 77(4):1231-1244. PubMed ID: 34459002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The argument against the use of dupilumab in patients with limited polyp burden in chronic rhinosinusitis with nasal polyposis (CRSwNP).
    Hardison SA; Senior BA
    J Otolaryngol Head Neck Surg; 2023 Sep; 52(1):64. PubMed ID: 37759322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative real-world outcomes of dupilumab versus endoscopic sinus surgery in the treatment of severe CRSwNP patients.
    De Corso E; Porru DP; Corbò M; Montuori C; De Maio G; Mastrapasqua RF; Panfili M; Spanu C; Di Bella GA; D'Agostino G; Rizzuti A; Passali GC; Galli J
    Clin Otolaryngol; 2024 Jul; 49(4):481-489. PubMed ID: 38711363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP): A multicentric observational Phase IV real-life study (DUPIREAL).
    De Corso E; Pasquini E; Trimarchi M; La Mantia I; Pagella F; Ottaviano G; Garzaro M; Pipolo C; Torretta S; Seccia V; Cantone E; Ciofalo A; Lucidi D; Fadda GL; Pafundi PC; Settimi S; Montuori C; Anastasi F; Pagliuca G; Ghidini A; Cavaliere C; Maffei M; Bussu F; Gallo S; Canevari FRM; Paludetti G; Galli J;
    Allergy; 2023 Oct; 78(10):2669-2683. PubMed ID: 37203259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of dupilumab treatment versus endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps.
    Dharmarajan H; Falade O; Lee SE; Wang EW
    Int Forum Allergy Rhinol; 2022 Aug; 12(8):986-995. PubMed ID: 34919344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologics for chronic rhinosinusitis.
    Chong LY; Piromchai P; Sharp S; Snidvongs K; Webster KE; Philpott C; Hopkins C; Burton MJ
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013513. PubMed ID: 33710614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dupilumab in chronic rhinosinusitis with nasal polyposis: current status, challenges, and future perspectives.
    Li T; Yin J; Yang Y; Wang G; Zhang Y; Song X
    Expert Rev Clin Immunol; 2023; 19(8):939-948. PubMed ID: 37378551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP.
    Bachert C; Zinreich SJ; Hellings PW; Mullol J; Hamilos DL; Gevaert P; Naclerio RM; Amin N; Joish VN; Fan C; Zhang D; Staudinger H; Pirozzi G; Graham NMH; Khan A; Mannent LP
    Rhinology; 2020 Feb; 58(1):10-17. PubMed ID: 31671432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dupilumab Improves Outcomes in Patients with Chronic Rhinosinusitis with Nasal Polyps and Coexisting Asthma Irrespective of Baseline Asthma Characteristics.
    Busse WW; Pavord ID; Siddiqui S; Khan AH; Praestgaard A; Nash S; Jacob-Nara JA; Rowe PJ; Deniz Y
    J Asthma Allergy; 2023; 16():411-419. PubMed ID: 37096015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of dupilumab versus endoscopic sinus surgery for the treatment of type-2 chronic rhinosinusitis with nasal polyps: a preliminary report.
    Orlando P; Licci G; Kuitche D; Matucci A; Vultaggio A; Gallo O; Maggiore G
    Eur Arch Otorhinolaryngol; 2024 Mar; 281(3):1317-1324. PubMed ID: 37910208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of intranasal corticosteroids in chronic rhinosinusitis with nasal polyposis treated with dupilumab.
    Pecorari G; Piazza F; Borgione M; Prizio C; Galli Della Mantica G; Garetto M; Gedda F; Riva G
    Am J Otolaryngol; 2023; 44(5):103927. PubMed ID: 37245323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dupilumab (Dupixent
    Jansen F; Becker B; Eden JK; Breda PC; Hot A; Oqueka T; Betz CS; Hoffmann AS
    Eur Arch Otorhinolaryngol; 2023 Apr; 280(4):1741-1755. PubMed ID: 36242612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olfactory Outcomes With Dupilumab in Chronic Rhinosinusitis With Nasal Polyps.
    Mullol J; Bachert C; Amin N; Desrosiers M; Hellings PW; Han JK; Jankowski R; Vodicka J; Gevaert P; Daizadeh N; Khan AH; Kamat S; Patel N; Graham NMH; Ruddy M; Staudinger H; Mannent LP
    J Allergy Clin Immunol Pract; 2022 Apr; 10(4):1086-1095.e5. PubMed ID: 34628065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dupilumab improves health related quality of life: Results from the phase 3 SINUS studies.
    Lee SE; Hopkins C; Mullol J; Msihid J; Guillemin I; Amin N; Mannent LP; Li Y; Siddiqui S; Chuang CC; Kamat S; Khan AH
    Allergy; 2022 Jul; 77(7):2211-2221. PubMed ID: 35034364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of Prior Endoscopic Sinus Surgery Extent on Dupilumab Effectiveness in CRSwNP Patients.
    Alicandri-Ciufelli M; Marchioni D; Pipolo C; Garzaro M; Nitro L; Dell'Era V; Ferrella F; Campagnoli M; Russo P; Galloni C; Ghidini A; De Corso E; Lucidi D
    Laryngoscope; 2024 Apr; 134(4):1556-1563. PubMed ID: 37632705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dupilumab efficacy in patients with chronic rhinosinusitis with nasal polyps with and without allergic rhinitis.
    Peters AT; Wagenmann M; Bernstein JA; Khan AH; Nash S; Jacob-Nara JA; Siddiqui S; Rowe PJ; Deniz Y
    Allergy Asthma Proc; 2023 Jul; 44(4):265-274. PubMed ID: 37480206
    [No Abstract]   [Full Text] [Related]  

  • 20. Chinese Expert Consensus on the Use of Biologics in Patients with Chronic Rhinosinusitis (2022, Zhuhai).
    Hong HY; Chen TY; Yang QT; Sun YQ; Chen FH; Lou HF; Wang HT; Yu RL; An YF; Liu F; Wang TS; Lu MP; Qiu QH; Wang XD; Chen JJ; Meng CD; Xie ZH; Meng J; Zeng M; Xu CL; Wang Y; Yang YC; Zhang WT; Tang J; Yang YL; Xu R; Yu GD; Shi ZH; Wei X; Ye HP; Sun YN; Yu SQ; Zhang TH; Yong J; Hang W; Xu YT; Xu Y; Tan GL; Sun N; Yang G; Li YJ; Ye J; Zuo KJ; Zhang LQ; Wang XY; Yang AN; Xu YX; Liao W; Fan YP; Li HB
    ORL J Otorhinolaryngol Relat Spec; 2023; 85(3):128-140. PubMed ID: 37019094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.